MAY 1 0 2004 2

Signature

PTO/SB/21 (08-03)


Under the Po			Applica	ation Number	10/759,746
	ISMITTAL		Filing [Date	January 16, 2004
	ORM		First N	amed Inventor	E. Fernandez-Salas
(to be used for all cor	respondence after init	ial filing)	Art Uni	t	Not Yet Assigned
			Exami	ner Name	Not Yet Assigned
Total Number of Pages	in This Submission	12	Attorne	ey Docket Number	ALLE0014-104 (17355CIP4
		ENCLO	SURES (check all that apply)	
Fee Transmittal Fo	om	☐ Drawin	g(s)		After Allowance Communic Group
Fee Attached		Licensi	ing-related	d Papers	Appeal Communication to Appeals and Interferences
Amendment / Rep	ly	Petition	ו		Appeal Communication to (Appeal Notice, Brief, Reply
After Final			n to Conve onal Appl		Proprietary Information
Affidavits/decl	aration(s)		Power of Attorney, Revocation Change of Correspondence Address		Status Letter
Extension of Time	Request	Termin	ninal Disclaimer		Other Enclosure(s) (please identify below):
Express Abandon	ment Request	Request for Refund		ınd	
☐ Information Disclo		CD, Number of CD(s)		CD(s)	
Certified Copy of I		<u> </u>			
Document(s)	nomy	Rema	rks		
Response to Miss Incomplete Applic					
Response to Missing Parts under 37 CFR 1.52 or 1.53					
	SIGNA	TURE OF	APPLICA	ANT, ATTORNEY,	OR AGENT
Firm <i>or</i> Individual name	David A. Sadew	asser/Reg.	No. 55,5	87	
Signature	Dovid a. Ladeur May 6, 2004			elz	
Date	May 6	,2004			
	0		-	TE OF MAILING	

a. Sadewasser This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to confidete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Date

Mayo.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: E. Fernandez-Salas, et al.

Serial No.: 10/759,746 Group Art Unit: Not Yet Assigned

Filing Date: January 16, 2004 Examiner: Not Yet Assigned

For: METHODS OF SCREENING FOR TOXIN

AGONISTS AND ANTAGONISTS

DATE OF DEPOSIT: May 6, 2004
I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON
THE DATE INDICATED ABOVE AND IS ADDRESSED TO
THE COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VA 22313-1450

TYPED NAME: David A. Sadewasser REGISTRATION NO:55,587

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This I	nforma	tion Disclosure Statement is being filed:			
	within	three months of the filing date of the patent application.			
		three months of the date of entry into the national stage as set forth in R. § 1.491 of the international application.			
\boxtimes	before	the mailing date of a first Office Action on the merits.			
	mailin	the mailing date of a first Office Action on the merits, but before the g date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of ance under 37 C.F.R. § 1.311, and accordingly is accompanied by:			
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);			
		or			
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or			
		No fee is owed by the applicant(s).			
	In accordance with 37 C.F.R. § 1.129(a), this Information Disclosur Statement is being filed in connection with \Box the first or \Box second After Final Submission, and accordingly is accompanied by the Statement under 3 C.F.R. § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is attached.				
	after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 C.F.R. § 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).				
\boxtimes	•	s of references listed on the attached PTO Form SB/08A and PTO Form B, formerly known as PTO Form 1449 are enclosed.			
	EXCE	PT THAT:			
		In view of the voluminous nature of reference @@, and the likelihood that this reference is available to the Examiner, copies are not enclosed herewith.			
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.			

50-1275.

	Copies of references (AU-DB) listed on the attached PTO F SB/08A and PTO Form SB/08B, formerly known as PTO Form 1 were previously cited by or submitted to the U.S. Patent Trademark Office in parent application Serial No. 10/757,077, January 14, 2004, Serial No. 10/163,106, filed on June 4, 2002 Serial No. 09/910,346, filed on July 20, 2001. References (AA-are newly cited United States patents and are not required to submitted.				U.S. Patent and 10/757,077, filed June 4, 2002 and eferences (AA-AT)	
			If any of the f Examiner, App Examiner's requ	licant will e	olications are nendeavor to su	not available to the pply copies at the
Staten	ient un	der 37 (C.F.R. § 1.97(e)			
	in the	The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.				
Fees						
\boxtimes	No Fe	e is owe	d by the applica	nt(s).		
	The 1 § 1.17	he Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. 1.17(p) is enclosed herewith.				
	The P	etition F	ee of \$130.00 u	nder 37 C.F.F	t. § 1.17(i)(1) is	s enclosed herewith.
Metho	od of P	ayment	of Fees			
	Attac subm	hed is a	a check in the luplicate.	amount of	\$	This form is
	Charg This	ge Depos form is s	sit Account No. ubmitted in dup	50-1275 in licate.	the amount of	\$·
\boxtimes	Pleas	e charge	any deficiency	or credit an	y overpayment	to Deposit Account

No fee or Statement is required under 37 C.F.R. § 1.97(b).

Respectfully submitted,

Dated: May 6, 2004

COZEN O'CONNOR, P.C. 1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 (215) 665-2000 – Telephone (215) 701-2013 - Facsimile David A. Sadéwasser Registration No. 55,587

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of | 7 Sheet

stitute for form 1449A/PTO

Complete if Known				
Application Number	10/759,746			
Filing Date	January 16, 2004			
First Named Inventor	E. Fernandez-Salas			
Art Unit	Not Yet Assigned			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	ALLE0014-104 (17335CIP4(BOT))			

	Γ	Document Number	U.S. PATENT	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevan
Examiner Initials *	Cite No.1	Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	AA	US-6,458,365	10/01/2002	Aoki, et al	
	AB	US- 5,766,605	06/16/1998	Sanders et al	
	AC	US- 5,714,468	02/03/1998	Dao	
	AD	US- 6,464,986	10/15/2002	Aoki et al	
	AE	US- 6,113,915	09/05/2000	Aoki et al	
	AF	US- 6,306,403	10/23/2001	Donovan	
	AG	US- 6,299,893	10/09/2001	Schwartz et al	
	AH	US- 5,670,484	09/23/1997	Binder	
	Al	US- 6,423,319	07/23/2002	Brooks et al	
	AJ	US- 6,139,845	10/31/2000	Donovan	
	AK	US- 6,143,306	11/07/2000	Donovan	
	AL	US- 5,437,291	08/01/1995	Pasricha et al	
	AM	US- 6,365,164	04/02/2002	Schmidt	
	AN	US- 6,063,768	05/16/2000	First	
	AO	US- 6,395,277	05/28/2002	Graham	
	AP	US- 6,265,379	07/24/2001	Donovan	
	AQ	US- 6,358,513	03/19/2002	Voet et al	
	AR	US- 6,328,977	12/11/2001	Donovan	
	AS	US- 6,306,423	10/23/2001	Donovan	
	AT	US- 6,312,708	11/06/2001	Donovan	

		FOREIGN PA	TENT DOCU	MENTS		
		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
	BD	WO94/15629	07/21/94	AS Synapse Biol.		
	ļ					

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 (and by the USPTO to process) an application. hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

		Under the Paperwo	ork Keau	CORON ACTOR 1995, NO DESCRIS	are required to respond to a concession	
	Substitute	Substitute for form 1449A/PTO			Complete if Known	
					Application Number	10/759,746
	INFO	RMATION	DIS	CLOSURE	Filing Date	January 16, 2004
STATEMENT BY APPLICANT					First Named Inventor	E. Fernandez-Salas
	JIA		, , , ,		Art Unit	Not Yet Assigned
		(Use as many sh	eets as	necessary)	Examiner Name	Not yet Assigned
_	Sheet	2	of	7	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))
	OHOOL	1 -	1 .	i .		•

			U.S. PATENT	OCUMENTS		
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevan	
Initials *	No.1	Number - Kind Code ² (if known)	MIM-DD-1111		Figures Appear	
	AU	US-5,053,005	10/01/1991	Borodic		
	AV	US- 5,174,468	02/03/1998	Binder		
	AW	US- 5,721,215	02/24/1998	Aoki et al		
	AX	US- 5,989,545	11/23/1999	Foster et al		
	AY	US- 6,113,915	09/05/2000	Aoki et al		
	AZ	US- 5,939,070	08/17/1999	Johnson et al		
	BA	US- 5,766,605	06/16/1998	Sanders et al		
	ВВ	US- 5,437,291	08/11/1995	Pasricha et al		
	ВС	US- 4,932,936	06/12/1990	Dykstra et al		
		US-				
		US-				
	1	US-				
		US-				
	1	US-				
		US-				
		US-				
		US-				
		US-				
	1	US-	l			
		US-				

	FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No. ¹	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶	
	<u> </u>		<u> </u>				
	 						
	1						
					<u> </u>	<u> </u>	

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Usptanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \(^5\) Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE				Application Number	10/759,746
				Filing Date	January 16, 2004
STAT	STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	E. Fernandez-Salas	
•			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	13	of	7	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))

		NON PATENT LITERATURE DOCUMENTS	T
Examiner	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	BE	ADENIS, et al., J. Fr. Ophthamol. (1990) 13:259-264.	
	BF	BINZ, et al., J. Biol. Chem. (1990) 265:9153-9158.	
	BG	BLITZER, et al., Ann. Otol. Rhinol Laryngol. (1985) 94:591-594.	
	вн	BRIN, et al., Advances in Neurology, Vol. 50: Dystonia 2 (1988), pp. 599-608.	
	ВІ	CENCI DI BELLO, et al., Eur. J. Biochem. (1994) 219:161-169.	
	BJ	COHN, et al., Neurology (1987) 37 (3 Supp. 1):123-124.	
	ВК	DARSOW, et al., J. Cell Biol. (1998) 142:913-922.	
	BL	ELSTON, et al., Br. J. Opthamol. (1985) 69:718-724.	
	ВМ	FAUCI, et al., "Harrison's Principles of Internal Medicine, 14 th ed., (1998) McGraw-Hill.	
	BN	ELSTON, et al., Br. J. Opthamol. (1985) 69:891-896.	
	во	GALLI, et al., Ceil (1998) 9:1437-1448.	

Examiner	Date
Signature	Considered
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND Information Officer, U.S. Patent and Trademark Office, U.S. Commissioner for Patents. P.O. Box 1450, Alexandria VA 22313-FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known Substitute for form 1449B/PTO 10/759,746 Application Number INFORMATION DISCLOSURE January 16, 2004 Filing Date STATEMENT BY APPLICANT E. Fernandez-Salas First Named Inventor Not Yet Assigned Art Unit Not Yet Assigned Examiner Name (Use as many sheets as necessary) ALLE0014-104 (17335CIP4(BOT)) Attorney Docket Number of 7 Sheet

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
miliais	ВР	JANCOVIC, et al., Neurology (1987) 37:616-623.	
	BQ	KADKHODAYAN, et al., Protein Express. Purif. (2000) 19:125-130.	
	BR	KOZAKI, et al., J. Med. Sci. Biol. (1981) 34:61-68.	
	BS	LACY, et al., Nat. Struct. Biol. (1998) 5:898-902.	
	ВТ	LI, et al., Biochemistry (1994) 33:7014-7020.	<u> </u>
	BU	MAISEY, et al., Eur. J. Biochem. (1988) 177:683-691.	
	BV	MARTINEZ-ARCA, et al., J. Cell Biol. (2000) 149:889-899.	
	BW	MILTON, et al., Biochemistry (1992) 31:8799-8809.	
	вх	MINTON, in Clostridial Neurotoxins: the molecular pathogenesis of tetanus and botulism, Montecucco, ed., Springer Verlag, NY, 1995, pp. 161-194.	
	ВУ	PEDEN, et al., J. Biol. Chem. (2001) 276:49183-49187.	
	BZ	SWAIN, et al., Peptide Res. (1993) 6:147-154.	

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

TEXAMINER: Initial if reference considered, whether of not clauton is in combinative with MFEF 609. Draw line through station in not in combinative and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

				Complete if Known			
Substitute	for form 1449B/PTO			Application Number	10/759,746		
INFO	RMATION [)IS	CLOSURE	Filing Date	January 16, 2004		
CTAI	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		PLICANT	First Named Inventor	E. Fernandez-Salas		
SIA	EIAICIA! DI	Λ '	1 2107	Art Unit	Not Yet Assigned		
		4	nooseani)	Examiner Name	Not Yet Assigned		
	(Use as many shee	of	necessary)	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))		

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
mitiais	110.	ZHOU, et al., Biochemistry (1995) 34:15175-15181.	Ì
	CA		
	СВ	SHIN, et al., J. Biol. Chem. (1991) 266:10658-10665.	
	 -	RASIBORSKA and CHARLTON, Can. J. Physiol. (1999) 77:679-688.	
	СС	RASIBONOVALIA STATEMENT	↓
	 	ERDAL, et al., Arch. Pharmacol. (1995) 351:67-78.	1
	CD	LIDAL, OCUM	
		RAGONA, et al., The Larangyscope (1999) 109:1344-1346.	
	CE		 -
	+	NAUMANN, et al., Eur. J. Neurol. (1999) 6:S111-S115.	
	CF		-
		KELLER, et al., FEBS Lett. (1999) 456:137-142.	
	CG		
	+	DIETRICH, et al., J. Cell. Biol. (1997) 138:271-281.	
	СН		+-
		GEISLER, et al., J. Biol. Chem. (1998) 273:21316-21323.	
	CI		+-
 -	+	TAN, et al., J. Biol. Chem. (1998) 273:17351-17360.	
	C1		_
	СК	LIU, et al., Trends Cell Biol. (1999) 9:356-363.	

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the complete and the use of the use o FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Under the Paperwo	ork Redu	ction Act of 1995, no persons	ale required to respond to a strain	
				1	Complete if Known
Substitute for	or form 1449B/PTC	,		Application Number	10/759,746
INFO	RMATION	DIS	CLOSURE	Filing Date	January 16, 2004
CTAT	EMENT R	YΔ	PPLICANT	First Named Inventor	E. Fernandez-Salas
SIAI	EIAILIA I D			Art Unit	Not Yet Assigned
	(Use as many sh	aata as	nocossan/)	Examiner Name	Not Yet Assigned
 	(Use as many sn		7	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))
Sheet	6	of	<u> </u>	Altonio) Decision	

		NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
miliais	110.	CAI and SINGH, Biochemistry (2001) 40:4693.	
	CL		}
	СМ	TIKKANEN, et al., Traffic (2000) 1:631-640.	
		RAPAPORT, et al., EMBO J. (1998) 17:2148-2155.	
	CN	TAI AT ONLY OR AND A TOTAL OR A T	
		MIRANDA, et al., JBC Papers in Press (2001) 1-35.	
	СО		
		COWLES, et al., Cell (1997) 91:109-118.	
	CP		-
	┼	AOKI, et al., J. Neuroi. (2001) 248 (Supp 1):3-10.	
	ca		┥
		AOKI, Toxicon. (2001) 12:1815-1820.	
	CR		+
	+	"Protein Turnover and Autograpjy," American Society for Cell Biology.	1
	cs		+
		WIEGAND, et al., Nauny Schmiedberg's Arch. Pharmacol. (1976) 292:	
l	СТ		+
	+	HABERMAN, Nauny Schmiedberg's Arch. Pharmacol. (1974) 281:	
ļ	CU		
	CV	THOMPSON, et al., Eur. J. Biochem. (1990) 189:73.	

Examiner Signature	Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation it not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual to complete, including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Under the Paperwork Reduction Act of 1995, no per- bistitute for form 1449B/PTO NFORMATION DISCLOSURE TATEMENT BY APPLICANT				Complete if Known
Substitute	for form 1449B/	PIO		Application Number	10/759,746
INFO	RMATIO	N DIS	CLOSURE	Filing Date	January 16, 2004
CTAI	NFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	PPLICANT	First Named Inventor	E. Fernandez-Salas	
SIA	FIAIFIA	D .,,		Art Unit	Not Yet Assigned
	///	, chaote as	nocessarv)	Examiner Name	Not Yet Assigned
	(Use as man)		7	Attorney Docket Number	ALLE0014-104 (17355CIP4(BOT))
Sheet_		of	<u></u>		

	NON PATENT LITERATURE DOCUMENTS	
Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
110.		
cw		
сх	285:1059-1070.	
CY	ESWARAMOORTHY, et al., "A novel mechanism for Clostridium botulinum neurotoxin inhibition," Biochemistry (2002) 41:9795-9802.	L
ļ	are the first state of a subscillular localization an important factor for Botulinum neurotoxin duration of	
cz	action?," Naunyn Schmiedebergs Arch. Phairiach. (2002) 656 (65pp).	
DA	implications for the duration of action of the different scrotypes,	
DB	STEWARD, et al., "BoNT/A light chain and the dileucine motif: potential implications for light chain localization and neurotoxin duration of action," Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R44.	
		-
+		
	No.1 CW CX CY CZ DA	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. CW DI BELLO, et al., Eur. J. Biochem. (1993) 219:161. CX ARNON, et al., "Botulinum toxin as a biological weapon: medical and public health management," JAMA (2001) 285:1059-1070. CY ESWARAMOORTHY, et al., "A novel mechanism for Clostridium botulinum neurotoxin inhibition," Biochemistry (2002) 41:9795-9802. CZ AOKI, et al., "Is the light chain subcellular localization an important factor for Botulinum neurotoxin duration of action?," Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R10. FERNANDEZ-SALAS, et al., "Localization of BoNT light chains in neuronal and non-neuronal cell lines, implications for the duration of action of the different serotypes," Naunyn Schmiedebergs Arch. Pharmacol. (2002) 365 (Suppl 2):R19.

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

[&]quot;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by This collection of information). Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments of the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief case. Any comments of the suggestions for reducing this burden, should be sent to the Chief case. FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.